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Macromolecular crystallography relies on the availability and
quality of single crystals; these are typically obtained through
extensive screening,which has a very low intrinsic success rate.
Crystallization is not a completely stochastic process and
many proteins do not succumb to crystallization because of
speciﬁc microscopic features of their molecular surfaces.
It follows that rational surface engineering through site-
directed mutagenesis should allow a systematic and signiﬁcant
improvement in crystallization success rates. Here, one such
established strategy, surface-entropy reduction (SER), is
discussed, including its successes, limitations and possible
future developments.
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1. Introduction
Single crystals constitute an essential prerequisite for struc-
tural investigations of biological macromolecules using X-ray
diffraction. Good-quality high-resolution diffraction data
virtually guarantee the success of structure determination and
high precision of the resulting atomic model. The vast majority
of problems encountered in crystal structure determination
can typically be traced back to data-quality issues caused by
crystal imperfections, poor resolution, unusual cases of
pseudosymmetry, anisotropic diffraction, twinning and so
forth. Consequently, although the primary focus of structural
biology is on the macromolecule that makes up a crystal, there
is also considerable interest in the physical properties,
nucleation and growth of the crystals themselves.
As vividly illustrated by the statistics assembled by various
Structural Genomics Centers, in spite of considerable progress
in the technology of liquid-handling and crystallization
robotics, the overall success rate of canonical crystallization
screening is low, ranging from at best 10–30% for small
prokaryotic proteins to only a few percent for a representative
range of eukaryotic proteins, including those from the human
proteome (Page, 2008). However, these statistics do not reﬂect
the true nature of the problem: many proteins do not succumb
to crystallization in spite of extensive screening, while others
may yield a variety of crystal forms in relatively few condi-
tions. Crystallization is not really a completely stochastic
process and is clearly determined by the microscopic nature
of the protein’s surface. Thus, the modiﬁcation of protein
samples through recombinant methods constitutes an effective
and rational approach to the problem of poor success rates in
crystallization (Dale et al., 2003).It has long been recognized that variations in amino-acid
sequences even among closely homologous proteins can cause
dramatic differences in their ability to form crystals (Campbell
et al., 1972; Kendrew et al., 1954; D’Arcy et al., 1999). However,
until recently it has not been possible to identify the exact
relationship between speciﬁc microscopic surface features and
the propensity of proteins to yield crystals. Instead, protein
engineering was aimed primarily at protein stabilization and
the removal of unstructured or unstable motifs that are likely
to interfere with crystallization. I reviewed these methods
recently (Derewenda, 2010). Although these strategies have
helped with the crystallization of numerous important targets,
they have not solved all of the problems. Numerous proteins
that are made up of a single domain, fully folded and stable,
are still recalcitrant to crystallization screens.
To address the crystallization bottleneck, several years ago
we proposed a new strategy of surface engineering based on
the concept of surface-entropy reduction (SER). Brieﬂy, we
argued that the transient protein–protein interactions that
underlie nucleation and crystal growth are impeded by the loss
of amino-acid side-chain entropy when the large and polar
amino acids that are typically located on the protein’s surface
are incorporated into crystal contacts with concomitant loss of
degrees of conformational freedom. We hypothesized that
mutating amino acids such as Lys, Glu and Gln to smaller
amino acids such as Ala might create surface patches that are
conducive to forming thermodynamically favourable inter-
actions, ultimately forming crystal contacts (Longenecker et
al., 2001; Mateja et al., 2002). The concept was validated
experimentally using a model system, i.e. the globular domain
of the human Lys- and Glu-rich protein RhoGDI (Rho-
GTPase guanine nucleotide dissociation inhibitor), and then
successfully used to obtain a plethora of novel crystal struc-
tures. These studies established that in general terms mutating
two to three high-entropy residues situated next to or very
close to each other in sequence yields the most successful
outcome (Garrard et al., 2001; Longenecker et al., 2001). More
recently, bioinformatics analyses showed that intermolecular
contacts in known crystal structures are indeed depleted in
high-entropy side chains (Cies ´lik & Derewenda, 2009) and
that a high content of amino acids such as Lys and Glu
correlates negatively with probability of crystallization (Price
et al., 2009). Surface-entropy reduction (or SER) has been
the subject of several reviews (Derewenda, 2004, 2010;
Derewenda & Vekilov, 2006). A server has been developed for
the automated design of protein variants with enhanced
crystallizability based on amino-acid sequence information
(Goldschmidt et al., 2007).
In this short article, I present an overview of what has been
learned from the application of SER in numerous laboratories
and comment on what future developments in this ﬁeld might
be expected.
2. The application and impact of SER
To date, more than 160 depositions of crystal structures based
on crystals generated by the SER method have been made in
the Protein Data Bank, attesting to the widespread popularity
and success of this approach to crystallization. A gallery of
most of the SER structures can be seen at the dedicated
website http://ginsberg.med.virginia.edu/Ser/ and a review
discussing these structures is in preparation. Among them
are  60 novel proteins, seven protein–protein complexes, a
signiﬁcant number of protein complexes with small molecules
used in drug design and two membrane proteins.
There are two obvious trends. First and foremost, the most
signiﬁcant impact of the SER strategy is on the crystallization
of novel protein targets and their complexes that are recalci-
trant to crystallization in the wild-type form. A number of
biologically important high-proﬁle structures have been
solved using SER crystals. For example, the CUE–ubiquitin
complex only succumbed to crystallization with a mutated
CUE domain of Vps9p (Prag et al., 2003). The structure offers
critical insight into the conjugation of ubiquitin in numerous
signalling pathways. SER also allowed for the crystallization of
the intact Hsc70 chaperone and visualization of the interaction
between its two domains, with important implications for the
understanding of the allosteric mechanism (Jiang et al., 2005).
One of the most spectacular successes of SER was the crys-
tallization of EscJ, a component of the type III secretion
system, allowing crystal structure determination at 1.8 A ˚
resolution (Yip et al., 2005). This structure helps in under-
standing key aspects of virulence in Gram-negative pathogens
(Fig. 1). A crystal structure of the ALIX/AIP programmed cell
death 6-interacting protein is vital to the understanding of the
mechanisms involved in retrovirus budding and endosomal
protein sorting (Fisher et al., 2007). The SER-engineered
ALIX also made it possible to crystallize its complex with the
YPX(n)L late domains of HIV-1 and EIAV (Zhai et al., 2008).
The crystal structure of the complex of c-Src with its regulator
Csk obtained using a mutated variant of Csk provided a
mechanistic explanation for the unusual speciﬁcity of Csk
kinases (Levinson et al., 2008). The complex of the NEMO
Uban motif with diubiquitin, crystallized using an SER variant
of NEMO (Rahighi et al., 2009), provided an explanation
for the detrimental effect of NEMO mutations in patients
suffering from X-linked ectodermal dysplasia and immuno-
deﬁciency. Recently, an HIV-capsid component was crystal-
lized by SER (Pornillos et al., 2009); the structure will help in
understanding the maturation of HIVand facilitate structure-
based drug-design efforts.
The second application of SER, particularly in pharma-
ceutical companies, is to use the strategy to manipulate the
target protein so as to generate crystal forms that are more
suitable for drug discovery (i.e. higher resolution data, expo-
sure of the active site to solvent) than those obtained for the
wild-type protein. Among such successfully engineered drug
targets are HIV reverse transcriptase (Bauman et al.,
2008; Das et al., 2008) and beta-site amyloid precursor
protein-cleaving enzyme (BACE-1), an important target in
Alzheimer’s disease (Yang et al., 2009; Rajapakse et al., 2006;
Coburn et al., 2006). Many other investigations are under way
but have not yet been published owing to intellectual property
concerns.
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crystallization?
The vast majority (>90%) of crystals obtained through SER
show that the crystal contacts are intimately mediated by the
mutated surface patches. There are two principal variations in
this respect: the contacts can be homotypic (i.e. two identical
patches interact across an interface generated by a crystallo-
graphic or noncrystallographic dyad) or heterotypic (i.e.
where the mutated patch interacts with a different surface
patch on an adjacent molecule; this is typically observed for
molecules related by translation or screw axes; Fig. 2). It is
obvious from these data that the SER strategy does in fact
allow direct engineering of crystal contacts by creating surface
patches that are signiﬁcantly more conducive to cohesive
interactions than the wild-type molecular surface. Several
distinct mechanisms may be in play. Firstly, as suggested by the
original hypothesis, surface patches depleted in high confor-
mational entropy residues might preferentially form thermo-
dynamically favourable crystal contacts. Also, in the absence
of large ﬂexible side chains the solvent-accessible backbone
amide and carbonyl groups have a higher potential to form
hydrogen bonds to water molecules and organise a network
of ordered solvent which is released upon nucleation, with
additional entropy gain. Release of water from the protein’s
surface is the primary entropic driving force for crystallization
(Vekilov, 2003; Vekilov et al., 2002). Moreover, the exposed
backbone may mediate direct intermolecular hydrogen bonds,
conferring stereochemical speciﬁcity on crystal contacts.
Finally, patches created by alanines or other small aliphatic
amino acids generate cohesive interactions through the
hydrophobic effect.
All these phenomena are quite close in their nature to those
that govern biologically relevant intermolecular interfaces. It
has been argued in the past that crystal contacts and biological
interfaces are sufﬁciently distinct in structure to allow largely
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Figure 2
Two types of contacts commonly found in crystals obtained by SER
engineering. (a) A homotypic symmetric contact creating a crystallo-
graphic dimer in the RGSL domain of PDZ-RhoGEF (PDB entry 1htj;
Longenecker et al., 2001). Alanines replacing Lys463, Glu465 and Glu466
are shown as magenta spheres. The twofold axis is perpendicular to the
plane of the drawing. (b) Heterotypic contacts (arrows) that mediate
interactions between noncrystallographic dimers of a putative NTP
pyrophosphorylase (PDB entry 3n77). The dimer interface is mediated by
a wild-type surface.
Figure 1
The crystal structure of the Escherichia coli EscJ protein, a molecular
platform for type III secretion, solved using crystals with SER surface
engineering (PDB entry 1yj7; Yip et al., 2005). (a) The content of the
asymmetric unit, an EscJ tetramer (each subunit is coloured differently),
with the location of the three mutations in the solvent-exposed loop
(E62A,K63A,E64A) indicated by arrows; the three alanines introduced
by mutagenesis are shown as magenta spheres. (b) The assembly of the
EscJ proteins into a 24-unit ring superstructure representative of the
early stage of assembly of the type II secretion system (Yip et al., 2005).
Note that the mutated patches mediate the only crystal contacts, copied
by the sixfold screw axis 65, perpendicular to the plane of the diagram.automated discrimination and annotation (Bahadur &
Zacharias, 2008; Bahadur et al., 2004; Ofran & Rost, 2003).
Biological interfaces tend to be signiﬁcantly larger than
average crystal contacts and their amino-acid composition
shows more pronounced deviations from random patches than
that in crystal contacts. All of this is true, but these analyses
overlook the fact that not all of the crystal contacts, as iden-
tiﬁed simply by physical proximity, must in fact be cohesive
and thermodynamically relevant contacts. Molecules can be
brought within physical contact in the incipient crystal nucleus
in serendipitous ways, driven by the thermodynamic ‘collapse’
of the nucleus. Our preliminary investigation shows that
crystal contacts can either be cohesive and contribute to the
thermodynamic stability and growth of the crystals (i.e.
primary contacts) or they can be repulsive and forced
(secondary contacts). Because all analyses to date assume that
physical proximity (e.g. distance criterion) determines all
crystal contacts, the outcome of these studies may be biased
and therefore may not faithfully reveal the exact nature of
cohesive primary crystal contacts.
4. The current and potential success rate of SER
An often-asked question is how much does SER increase the
probability of obtaining crystals? Unfortunately, there is no
unambiguous answer. In the only truly systematic study of the
application of SER to diverse human targets, it has been found
that SER rescued three out of the 20 tested proteins (15%)
that did not crystallize in their wild-type form (A. Edwards,
University of Toronto, personal communication). It should be
recognized, however, that virtually all of the applications of
SER involve the engineering of a single surface patch, with a
maximum of three amino acids mutated to Ala. In approxi-
mately half of these structures the mutated patches form
homotypic contacts (see above, x3), leading to crystallographic
homodimers related by a twofold axis or a noncrystallographic
dyad. It is possible that even transient dimerization signiﬁ-
cantly increases the propensity of the protein to crystallize
(Banatao et al., 2006). However, this means that once such a
homodimer forms the engineered patch has no further role
to play and other wild-type surface patches must provide
suitable intermolecular contacts for the formation of a three-
dimensional crystal. If no such suitable patches are present
then crystallization will not occur. This strongly suggests that
engineering of second- and third-order cohesive contacts may
be necessary to bring the success rate of SER closer to the
highly desired 100% range. An interesting recent study indeed
supports this notion: the human vaccinia-related kinase 1
(PDB entry 3op5) was crystallized after four patches, con-
taining a total of 11 mutations, had been introduced based
on the SERp server predictions. The asymmetric unit of these
crystals contains four molecules; while one set of mutations
is located in the disordered C-terminus, the other three each
mediate unique crystal contacts. This example clearly shows
that SER can and should be developed further so that in
principle any macromolecule can be coerced to form crystals
mediated by a set of engineered contacts.
5. Can SER be helpful for membrane-protein
crystallization?
It is particularly encouraging that SER is being successfully
applied to membrane proteins, although there are only two
such examples to date: the complex of the K
+-gated channel
KChIP1 with the Kv channel-interacting protein (Kv4.3 T1)
crystallized using a double mutant K(160,167)A of the latter
(Pioletti et al., 2006) and the impressive crystal structure of the
BetP Na
+/betaine symporter obtained using crystals of a triple
variant E(44,45,46)A (Ressl et al., 2009). In the latter case the
mutations occur within a disordered fragment of the structure
and do not participate in the crystal contacts.
In the general case SER is not directly applicable to
membrane proteins. The SER strategy assumes that the
protein’s surface is uniformly populated with large polar
amino acids and this assumption breaks down for membrane
proteins. Ironically, the transmembrane portions of membrane
proteins typically have an amino-acid composition that is
much closer to that desired for crystal contacts, but in this case
these nonpolar surfaces are responsible for aggregation and
are shielded by detergents. The remaining solvent-exposed
surfaces are small and offer very limited opportunities for
engineering. Moreover, while the loss of a few polar amino
acids in a globular protein does not compromise its solubility
(see below), in a membrane protein such mutations are not
expected to have only benign consequences. Thus, other
approaches might be more suitable (see x7).
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Figure 3
Solubility data in PEG 6000 for selected mutants of RhoGDI (Cooper
et al., 2007) plotted on a logarithmic scale following Cohn’s equation,
logcp = B   Kc, where cp is the protein concentration, c is the precipitant
concentration, B is the idealized protein solubility at c = 0 and K is a
protein-dependent constant. For all mutants, the solubility in PEG 6000 is
systematically lowered and follows the pattern observed by Trevino et al.
(2007). Importantly, the K parameter appears unchanged, so that the
solubility lines are approximately parallel. The replacement of lysines by
alanines causes only a marginal decrease in solubility; the effect is more
signiﬁcant when threonines are introduced and is the largest with
tyrosines. Replacing glutamates by alanines causes a signiﬁcantly larger
solubility reduction. Solubility was measured at room temperature at
pH 8.0 (buffered) as a function of PEG 6000 concentration.6. SER and protein solubility
When the SER concept was ﬁrst published, it was suggested
that mutations of the K!A and E!A type are bound to
decrease the protein solubility and thereby promote crystal-
lization indirectly. However, the fact that mutated patches are
almost invariably involved in mediating crystal contacts (see
above) attests to the contrary. Solubility is a macroscopic
property and while it is determined by the amino-acid content
(or more precisely the surface amino-acid composition), it is
not directly correlated with local microscopic surface struc-
ture. To better understand the impact of speciﬁc surface
mutations on solubility, we initiated systematic investigations
of the solubility of select SER mutants of RhoGDI (these
are currently being prepared for publication). Fig. 3 shows
representative data for the solubility of four double mutants
in polyethylene glycol. It is clear that the replacement of two
neighbouring lysines by alanines causes only a marginal
reduction in solubility; the replacement of glutamates by
alanines is more signiﬁcant but not dramatic. In contrast, the
replacement of a lysine and a glutamine by two tyrosines
reduces the solubility of the protein by an order of magnitude.
Our results are consistent with the recent systematic study of
the impact of surface mutations on protein solubility using
ribonuclease as a model system that shows that the replace-
ment of Lys by Ala or Ser does not reduce solubility; in fact,
Ser mutants should be more soluble than the wild-type protein
(Trevino et al., 2007). Further studies will allow the design of
mutations that simultaneously enhance crystallizability and
modify solubility in a desired way.
7. SER-enhanced chaperones
One of the exciting new applications of SER is the engineering
of proteins that serve as crystallization chaperones. Two
complementary strategies are possible. Firstly, it has been
established for some time that fusion proteins containing a
carrier protein and the target molecule can sometimes crys-
tallize more effectively owing to the carrier protein, which
may mediate some or most of the crystal contacts. Various
such carrier proteins have been tried, but maltose-binding
protein (MBP) has been the most successfully used molecule
(Smyth et al., 2003). Recently, it has been suggested that an
engineered MBP might be even more effective in promoting
the crystallization of a fusion protein, and indeed a D82A,
K83A, K239 variant was successfully utilized to crystallize the
RACK1 protein (Ullah et al., 2008). The other option is to use
phage display to generate recombinant Fab fragments or other
engineered scaffolds (Koide, 2009; Gebauer & Skerra, 2009).
These scaffolds could also be engineered for enhanced crys-
tallizability by SER, although this has not yet been achieved.
8. Concluding remarks
The SER strategy has convincingly demonstrated that
macromolecular crystal engineering is a useful and effective
tool with the promise of improving overall crystallization
success rates well above those stemming from pure canonical
screening. However, it is also clear that more elaborate
approaches will be required in order to tackle the most
complex problems such as the crystallization of membrane
proteins or large complexes. Work on these questions is in
progress.
The research on protein crystallization in the author’s
laboratory has been supported by the National Institute of
General Medical Sciences.
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